Literature DB >> 7523505

A region of the third variable loop of HIV-1 gp120 is recognized by HLA-B7-restricted CTLs from two acute seroconversion patients.

J T Safrit1, A Y Lee, C A Andrews, R A Koup.   

Abstract

HIV-1 envelope-specific CTL clones were isolated from the peripheral blood of two patients from within weeks of seroconversion. These clones were CD8+ and restricted by the HLA-B7 molecule. The minimum epitope recognized by the clones was determined to be the 30-amino acid (aa) sequence RPNNNTRKSI within the third variable (V3) loop of the envelope glycoprotein gp120. The aa sequence of this epitope is consistent with the motif found in naturally processed peptides eluted from HLA-B7 molecules. This region of the V3 loop is reasonably well conserved among clade B and some nonclade B isolates of HIV-1, especially at the anchor residues that determine binding to the HLA-B7 molecule. Using peptides based upon virus sequences present within each patient, we determined that autologous viruses were recognized by the clones, and we detected no escape variants from the initial clonal response during the acute phase of infection. Interestingly, a serine to arginine change at position 9 of the epitope abrogated clone recognition in one of the patients. This aa change is one factor that has been associated with a change from a nonsyncytium-inducing to a syncytium-inducing phenotype of HIV-1, raising the possibility that in HLA-B7-expressing patients, escape from this clonal CTL response and a change in viral phenotype may be linked. This study demonstrates that human CTL can be generated against sequences within the third variable loop of HIV-1 gp120. Because multiple vaccine strategies are based upon the V3 loop of HIV-1 gp120, this defined epitope can be exploited in determining the ability of certain vaccines to stimulate a CTL response in a select population of individuals.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7523505

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Intrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period.

Authors:  V V Lukashov; C L Kuiken; J Goudsmit
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

2.  Preventive and therapeutic AIDS peptide vaccines.

Authors:  A Rubinstein; S Cryz
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

3.  Characterization of the functional properties of env genes from long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  R I Connor; K E Sheridan; C Lai; L Zhang; D D Ho
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

4.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Genetic variation in a human immunodeficiency virus type 2 live-virus Macaca nemestrina vaccine model.

Authors:  A Radaelli; G Kraus; A Schmidt; P Badel; J McClure; S L Hu; W Morton; C De Giuli Morghen; F Wong-Staal; D Looney
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Patterns of changes in human immunodeficiency virus type 1 V3 sequence populations late in infection.

Authors:  J A Nelson; F Baribaud; T Edwards; R Swanstrom
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

7.  Evolution of human immunodeficiency virus type 1 in perinatally infected infants with rapid and slow progression to disease.

Authors:  F Salvatori; S Masiero; C Giaquinto; C M Wade; A J Brown; L Chieco-Bianchi; A De Rossi
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

8.  A dominant role for CD8+-T-lymphocyte selection in simian immunodeficiency virus sequence variation.

Authors:  David H O'Connor; Adrian B McDermott; Kendall C Krebs; Elizabeth J Dodds; Jacqueline E Miller; Edna J Gonzalez; Timothy J Jacoby; Levi Yant; Helen Piontkivska; Ralph Pantophlet; Dennis R Burton; William M Rehrauer; Nancy Wilson; Austin L Hughes; David I Watkins
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity.

Authors:  Barney S Graham; M Juliana McElrath; Michael C Keefer; Kyle Rybczyk; David Berger; Kent J Weinhold; Janet Ottinger; Guido Ferarri; David C Montefiori; Don Stablein; Carol Smith; Richard Ginsberg; John Eldridge; Ann Duerr; Pat Fast; Barton F Haynes
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

10.  Heteroduplex mobility assay and phylogenetic analysis of V3 region sequences of human immunodeficiency virus type 1 isolates from Gulu, northern Uganda. The Italian-Ugandan Cooperation AIDS Program.

Authors:  L Buonaguro; E Del Guadio; M Monaco; D Greco; P Corti; E Beth-Giraldo; F M Buonaguro; G Giraldo
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.